SA55 nasal spray
/ Sinovac
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 26, 2025
Safety and Intranasal Retention of a Broad-Spectrum Anti-SARS-CoV-2 Monoclonal Antibody SA55 Nasal Spray in Healthy Volunteers: A Phase I Clinical Trial.
(PubMed, Pharmaceutics)
- "This study demonstrated favorable safety and tolerability of the SA55 nasal spray in healthy volunteers, exhibited satisfactory neutralizing activity against Omicron variants intranasally, and indicated low systemic toxicity risk."
Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
September 21, 2023
SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Sinovac Life Sciences Co., Ltd.
New P1 trial • Infectious Disease • Novel Coronavirus Disease
1 to 2
Of
2
Go to page
1